Cue Biopharma, Inc. (CUE) vs Lineage Cell Therapeutics, Inc. (LCTX)
Cue Biopharma, Inc. and Lineage Cell Therapeutics, Inc. are both Biotechnology companies. Cue Biopharma, Inc. and Lineage Cell Therapeutics, Inc. are of similar size ($239.7M and $238.6M). Cue Biopharma, Inc. grew revenue faster over the last twelve months: 354.4% against 19.9%. Lineage Cell Therapeutics, Inc. has the higher net margin (−246.6% vs −435.8%) and the lower return on invested capital (−186.8% vs 0.00%). Across the 18 metrics below, Cue Biopharma, Inc. leads on 10 and Lineage Cell Therapeutics, Inc. on 8.
Valuation
Profitability
| Metric | CUE | LCTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 99.46% | 65.16% |
| Operating margin | (262.03%) | (205.23%) | 0.00% |
| Net margin | (435.83%) | (246.58%) | 0.00% |
| Free cash flow margin | (133.13%) | (186.43%) | 0.00% |
| Return on equity | (1,603.48%) | (60.35%) | (57.72%) |
| Return on assets | (459.60%) | (32.75%) | (49.22%) |
| Return on invested capital | 0.00% | (186.79%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack